This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $93.26, moving -1.43% from the previous trading session.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DJD
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK
by Zacks Equity Research
Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.
Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab
by Zacks Equity Research
Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.
Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab
by Kinjel Shah
FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.
Here's Why Merck (MRK) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
by Zacks Equity Research
Corcept (CORT) starts the phase II DAZALS study evaluating its selective cortisol modulator, dazucorilant for treating patients with amyotrophic lateral sclerosis.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $91.05, marking a +0.63% move from the previous day.
Merck (MRK) Posts Positive Results From PAH Drug Study
by Zacks Equity Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Stock Market News for Oct 10, 2022
by Zacks Equity Research
U.S. stock markets closed sharply lower on Friday following stronger-than-expected job data for September.
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
by Zacks Equity Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Exelixis' (EXEL) Growth Story Likely to Continue?
by Zacks Equity Research
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
by Zacks Equity Research
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $87.55 in the latest trading session, marking a +1.66% move from the prior day.
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
by Zacks Equity Research
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
by Zacks Equity Research
The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.
Should Invesco Dow Jones Industrial Average Dividend ETF (DJD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DJD
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $85.84, moving -0.39% from the previous trading session.
Atea (AVIR) Dengue Candidate Gets Fast Track Designation
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
Dow Jones ETF Avoids Bear Market: 4 Stocks in Green
by Sweta Killa
Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris
by Zacks Equity Research
Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United States
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
by Kinjel Shah
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.